109 related articles for article (PubMed ID: 8759071)
1. Endothelin and calcium antagonists in the skin microcirculation of patients with coronary artery disease.
Wenzel RR; Duthiers N; Noll G; Bucher J; Kaufmann U; Lüscher TF
Circulation; 1996 Aug; 94(3):316-22. PubMed ID: 8759071
[TBL] [Abstract][Full Text] [Related]
2. Endothelin receptor antagonists inhibit endothelin in human skin microcirculation.
Wenzel RR; Noll G; Lüscher TF
Hypertension; 1994 May; 23(5):581-6. PubMed ID: 8175165
[TBL] [Abstract][Full Text] [Related]
3. Enhanced vasoconstriction to endothelin-1, angiotensin II and noradrenaline in carriers of the GNB3 825T allele in the skin microcirculation.
Wenzel RR; Siffert W; Bruck H; Philipp T; Schäfers RF
Pharmacogenetics; 2002 Aug; 12(6):489-95. PubMed ID: 12172218
[TBL] [Abstract][Full Text] [Related]
4. Selective endothelin ETA and dual ET(A)/ET(B) receptor blockade improve endothelium-dependent vasodilatation in patients with type 2 diabetes and coronary artery disease.
Rafnsson A; Shemyakin A; Pernow J
Life Sci; 2014 Nov; 118(2):435-9. PubMed ID: 24607773
[TBL] [Abstract][Full Text] [Related]
5. Effects of calcium channel blockers on coronary vasoconstriction induced by endothelin-1 in closed chest pigs.
Egashira K; Pipers FS; Rush JE; Morgan JP
J Am Coll Cardiol; 1990 Nov; 16(5):1296-303. PubMed ID: 2229778
[TBL] [Abstract][Full Text] [Related]
6. Vascular effects of endothelin-1 in humans and influence of calcium channel blockade.
Kiowski W; Linder L; Erne P
J Hypertens Suppl; 1994 Jan; 12(1):S21-6. PubMed ID: 8207561
[TBL] [Abstract][Full Text] [Related]
7. Differential effects of calcium channel antagonists in the amelioration of radial artery vasospasm.
Bond BR; Zellner JL; Dorman BH; Multani MM; Kratz JM; Crumbley AJ; Crawford FA; Spinale FG
Ann Thorac Surg; 2000 Apr; 69(4):1035-40; discussion 1040-1. PubMed ID: 10800790
[TBL] [Abstract][Full Text] [Related]
8. ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro.
Maguire JJ; Davenport AP
Br J Pharmacol; 1995 May; 115(1):191-7. PubMed ID: 7647976
[TBL] [Abstract][Full Text] [Related]
9. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease.
Wenzel RR; Fleisch M; Shaw S; Noll G; Kaufmann U; Schmitt R; Jones CR; Clozel M; Meier B; Lüscher TF
Circulation; 1998 Nov; 98(21):2235-40. PubMed ID: 9826308
[TBL] [Abstract][Full Text] [Related]
10. Endothelin at pathophysiological concentrations mediates coronary vasoconstriction via the endothelin-A receptor.
Cannan CR; Burnett JC; Brandt RR; Lerman A
Circulation; 1995 Dec; 92(11):3312-7. PubMed ID: 7586319
[TBL] [Abstract][Full Text] [Related]
11. Endothelin-induced vasoconstriction and calcium antagonists.
Lüscher TF; Yang Z; Kiowski W; Linder L; Dohi Y; Diederich D
J Hum Hypertens; 1992 Dec; 6 Suppl 2():S3-8. PubMed ID: 1289511
[TBL] [Abstract][Full Text] [Related]
12. Effect of calcium antagonists on endothelin-induced contraction of isolated human resistance arteries: differences related to site of origin.
Sunman W; Martin G; Hair WM; Sever PS; Hughes AD
J Hum Hypertens; 1993 Apr; 7(2):189-91. PubMed ID: 8389874
[TBL] [Abstract][Full Text] [Related]
13. Endothelin in the pulmonary circulation with special reference to hypoxic pulmonary vasoconstriction.
Holm P
Scand Cardiovasc J Suppl; 1997; 46():1-40. PubMed ID: 9265559
[TBL] [Abstract][Full Text] [Related]
14. Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor.
Kiowski W; Lüscher TF; Linder L; Bühler FR
Circulation; 1991 Feb; 83(2):469-75. PubMed ID: 1846783
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of vascular responses to endothelin-1 of simian digital arteries that distribute their branches to the skin.
Haniuda K; Ito T; Chiba S
J Invest Dermatol; 1991 Dec; 97(6):1024-7. PubMed ID: 1748812
[TBL] [Abstract][Full Text] [Related]
16. Endothelins and their inhibition in the human skin microcirculation: ET[1-31], a new vasoconstrictor peptide.
Leslie SJ; Rahman MQ; Denvir MA; Newby DE; Webb DJ
Br J Clin Pharmacol; 2004 Jun; 57(6):720-5. PubMed ID: 15151517
[TBL] [Abstract][Full Text] [Related]
17. Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo.
Haynes WG; Strachan FE; Webb DJ
Circulation; 1995 Aug; 92(3):357-63. PubMed ID: 7634449
[TBL] [Abstract][Full Text] [Related]
18. Endothelin-A receptor antagonist inhibits angiotensin II and noradrenaline in man.
Wenzel RR; Rüthemann J; Bruck H; Schäfers RF; Michel MC; Philipp T
Br J Clin Pharmacol; 2001 Aug; 52(2):151-7. PubMed ID: 11488771
[TBL] [Abstract][Full Text] [Related]
19. Endothelin-1 induces vasodilation in human skin by nociceptor fibres and release of nitric oxide.
Wenzel RR; Zbinden S; Noll G; Meier B; Lüscher TF
Br J Clin Pharmacol; 1998 May; 45(5):441-6. PubMed ID: 9643615
[TBL] [Abstract][Full Text] [Related]
20. Evidence from receptor antagonists of an important role for ETB receptor-mediated vasoconstrictor effects of endothelin-1 in the rat kidney.
Wellings RP; Corder R; Warner TD; Cristol JP; Thiemermann C; Vane JR
Br J Pharmacol; 1994 Feb; 111(2):515-20. PubMed ID: 8004396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
